Menu Search
Equities

Eckert & Ziegler SE

EUZ:DUS

Eckert & Ziegler SE

Actions
  • Price (EUR)39.86
  • Today's Change3.38 / 9.27%
  • Shares traded200.00
  • 1 Year change+14.23%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.

  • Revenue in EUR (TTM)277.70m
  • Net income in EUR39.05m
  • Incorporated1997
  • Employees1.14k
  • Location
    Eckert & Ziegler SERobert-Roessle-Str.10BERLIN 13125GermanyDEU
  • Phone+49 309410840
  • Fax+49 30 941084112
  • Websitehttps://www.ezag.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.